Clinical trial remote monitoring software is not one category but a set of systems that support remote data acquisition, source document review, and centralized oversight. FDA guidance describes digital health technologies, or DHTs, as systems using computing platforms, connectivity, software, and sensors for healthcare and related uses [1]. The same term can cover a wearable sensor, a mobile application, or a cloud-based document review tool. For a sponsor or investigator, the first technical decision is therefore to name the workflow being monitored. A cardiac safety study may need continuous physiologic data with adjudication pathways, while a decentralized trial may need remote source data verification. These workflows impose different validation, data quality, and monitoring requirements. This article explains those decision points, the evidence limitations, and a concrete evaluation example without turning the topic into generic buying advice.

Defining the Remote Monitoring Workflow

FDA guidance frames DHTs by function rather than product category. A DHT for remote data acquisition can include hardware, software, or both, and may perform multiple functions, some of which may be device functions [1]. The guidance covers use in investigational new drug applications, investigational device exemptions, marketing applications, and drug or device development tool submissions [1]. This means the same software may be evaluated differently depending on whether it measures a biomarker, administers a clinical outcome assessment, or only manages documents. Sponsors should first state which trial activity the software supports and whether that activity creates a regulated electronic record.

The decentralized trials guidance separates electronic systems used to manage trial operations from systems that acquire clinical data. Electronic systems can manage informed consent, archive signed forms, and support local healthcare providers entering data into an electronic case report form [2]. Local providers may submit data directly into an eCRF or send documents through secure transfer to investigators who enter the data [2]. Remote trial personnel or local providers submitting data directly into the eCRF should appear on the sponsor's list of authorized data originators [2]. This distinction matters because document management software and clinical data acquisition software carry different validation and access control obligations.

Technical Decision Points in DHT Selection

A cardiac safety think tank convened through a public-private partnership with FDA identified hardware, processing algorithms, data storage, interpretation, and feedback streams as differences among remote monitors that can affect safety evaluations in studies [4]. The panel concluded that effective incorporation into trials requires standardized data streams, technological validation across populations, validation in appropriate use cases, data quality checks, systems to capture adverse events, and systems to evaluate falsified or fabricated data [4]. The panel also noted that predefined analyses may not accurately capture individual or group effects that adjudicate an adverse event [4]. These are not procurement preferences but technical prerequisites for using remote data in safety evaluations.

The FDA electronic systems guidance adds a risk-based approach to validation. Automated date and time stamps, audit trails, complete and accurate copies, and record retention are standard components of many electronic systems [6]. The guidance addresses part 11 applicability for systems that create, modify, maintain, archive, retrieve, or transmit electronic records, including DHTs used to remotely acquire data [6]. A sponsor evaluating software should therefore ask whether the vendor can demonstrate validation evidence for the specific functions used in the trial, not merely for the platform as a whole. Validation scope should follow the trial's risk profile and the criticality of the data.

A Concrete Evaluation Example: Remote Source Review for a Decentralized Cardiology Trial

As a suggestion, consider a sponsor evaluating remote source review for a decentralized cardiology trial with 40 sites. The evaluation would begin by listing the documents requiring SDV or SDR: informed consent forms, echocardiogram reports, and concomitant medication logs. The sponsor would then test whether the software can assign documents to monitors by site, apply redaction to protected health information, and produce an audit trail showing who viewed each document and when. This test should use de-identified sample documents, not live participant data.

The sponsor would also assess the workflow burden on sites. The remote monitoring study reported that 45.0% of uploaded photographs would not have been captured if direct data capture had been introduced [7]. A pilot with two or three sites could measure upload time per participant visit and compare it with on-site monitoring preparation. The sponsor should not assume the 45.0% figure applies to its trial, given the eight-participant sample and single-system design [7].

Finally, the sponsor would document validation evidence for the specific functions used, including automated date and time stamps, audit trails, and complete and accurate copies [6]. If the vendor claims 21 CFR Part 11 compliance, the sponsor should request the validation documentation and map it to the trial's risk assessment [5]. The evaluation ends with a written decision record stating which workflows the software supports, which data quality checks are in place, and which clinical or cost outcomes remain unmeasured.

Remote Source Review and Risk-Based Monitoring

Remote source review software addresses a different workflow: monitors acquiring documents for source data verification and source data review. Medidata describes its Remote Source Review as a cloud-based solution that automates document workflows to the right monitor and supports SDV and SDR for compliance and quality [5]. The vendor states the system is 21 CFR Part 11-compliant and includes redaction functionality to protect personally identifiable information and protected health information [5]. These are vendor claims about a specific product, not independent findings. A sponsor would need to verify the compliance statement against its own validation requirements and the trial's data protection obligations.

A small prospective study tested remote risk-based monitoring with eight participants in a randomized trial. Clinical staff photographed source documents and uploaded them to a secure cloud location for remote review, with later on-site monitoring used to confirm findings [7]. The study reported that 45.0% of uploaded photographs would not have been captured if direct data capture had been introduced [7]. The authors concluded that remote risk-based monitoring combined with direct data capture could reduce staff workload, but the study involved only eight participants and one remote monitoring system provided by a company whose president was a co-author [7]. The finding is suggestive, not generalizable.

Monitoring Continuous Remote Data Streams

Sensor-based digital health technologies create continuous data streams that require monitoring beyond traditional source verification. The DiMe sDHT Adoption Navigator identifies three parallel oversight areas: technical reliability and pipeline health, participant adherence and engagement, and clinical validity and safety oversight [8]. Technical failures can lead to missing, delayed, or compromised data, making early detection essential for data completeness and integrity [8]. Persistent connectivity issues may compromise the contemporaneous nature of data and should be investigated promptly [8]. Participant confusion, burden, or disengagement can create data gaps that undermine endpoint reliability even when systems function as designed [8].

The npj Health Systems framework for remote patient monitoring solutions emphasizes development steps that precede deployment: conceptualizing the construct to be measured, drawing on clinical guidelines, toxicity grading criteria, social listening, expert review, and expert consensus when needed [3]. Regulatory and quality compliance reviews are required for alignment with regulatory requirements and guidance for digital health solutions implemented in clinical trials [3]. The framework was illustrated with deployments for skin toxicities and stomatitis, where the RPM solution was noted to support earlier identification and management of skin toxicities, but further research was planned to establish clinical utility and validity in larger cohorts [3]. This is a development framework, not proof of clinical benefit.

Evidence Limitations and Unknowns

The available evidence supports feasibility and process improvements more than clinical outcomes. The npj Health Systems article states that evidence suggests RPM may improve patient engagement, with more accurate symptom reporting than during routine visits and better adherence to medication schedules, citing prior studies [3]. The article also notes that data sharing was not applicable because no datasets were generated or analyzed [3]. The cardiac safety panel provides recommendations and best practices but explicitly states that the manuscript does not constitute regulatory guidance [4]. FDA guidance documents themselves are nonbinding recommendations unless specific regulatory or statutory requirements are cited [2].

Several consequential questions remain unanswered by the retrieved sources. No source establishes that remote monitoring software improves trial endpoints, reduces serious adverse events, or lowers total trial cost in a controlled comparison. The eight-participant remote monitoring study cannot support claims about error detection rates across trials [7]. Vendor statements about compliance and efficiency are marketing claims that require independent verification [5]. Sponsors should document these unknowns in their evaluation rather than treating software selection as a settled evidence question. The appropriate posture is to define the monitored workflow, validate the specific data stream, and measure operational outcomes within the trial.